Promise and deceit: pharmakos, drug replacement therapy, and the perils of experience.
The problem of lying as a feature of medication compliance has been well documented in anthropological and clinical literatures. Yet the role of the lie-its destabilizing effects on the continuity of drug treatment and therapy, as a technology of drug misuse, or as a way to understand the neuro-chemical processes of treatment (pharmacotherapy "tricking" or lying to the brain)-has been less considered, particularly in the context of opioid replacement therapy. The following paper is set against the backdrop of a three-year study of adolescents receiving a relatively new drug (buprenorphine) for the treatment of opiate dependency inside and outside of highly monitored treatment environments in the United States. Lies give order not only to the experience of addiction but also to the experience of therapy as well. In order to better understand this ordering of experience, the paper puts the widely discussed conceptual duality of the pharmakon (healing and poison) in conversation with a perilously overlooked subject in the critical study of pharmacotherapy, namely the pharmakos or the personification of sacrifice. The paper demonstrates how the patient-subject comes to represent therapeutic promise by allowing for the possibility of (and often performing) deceit.
Department of Anthropology, Wayne State University, 656 W. Kirby, Detroit, MI, 48202, USA, toddemeyers@gmail.com.
Todd
T
Meyers
D000293:Adolescent; D000701:Analgesics, Opioid / Q000378:metabolism / Q000493:pharmacokinetics; D016739:Behavior, Addictive; D002047:Buprenorphine / Q000378:metabolism / Q000493:pharmacokinetics; D008192:Deception; D016903:Drug Monitoring; D006801:Humans; D009420:Nervous System / Q000187:drug effects*; D058850:Opiate Substitution Treatment / Q000379:methods / Q000523:psychology; D009293:Opioid-Related Disorders / Q000523:psychology / Q000628:therapy; D010686:Philosophy, Medical; D016320:Substance Abuse Treatment Centers; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control
D000701:Analgesics, Opioid; D002047:Buprenorphine